Kinase activity has not been detected for several CDK-related proteins, but they are still known as PFTK2, PCTK2 or CCRK, where 'K' stands for 'kinase'. Finally, most 'cyclins' do not cycle.

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

The partnership is expected to yield treatments that demonstrate efficacy and offer improved quality of life and tolerability ...

Proxygen GmbH has divulged molecular glue degraders comprising a cullin-ring E3 ligase (CRL)-binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...

Ryvu Therapeutics has initiated the Phase II trial, POTAMI-61, dosing the first subject with a small-molecule ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...

AKT regulates the cell cycle by phosphorylating FoxO1 and decreasing its transcription of CDK inhibitors p21 and p27. AKT, protein kinase B; CDK, cyclin dependent kinase; FoxO1, forkhead box O1 ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors ...